Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
07/21 ASTELLAS PHARMA : U.S. FDA Grants Orphan-Drug Designation to Astellas for Develo..
07/13 ASTELLAS PHARMA : Supports the Northern Kyushu Heavy Rain Relief Efforts
07/12 ASTELLAS PHARMA : Presentation material for Press Conference on July 11th (1.76 ..
07/07 ASTELLAS PHARMA : Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis ..
07/06 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Mirabegron for U..
07/05 ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index for the Sixth Consecut..
06/30 Global Pertussis Vaccine Market 2017 - Sanofi Pasteur, Astellas Pharma, Life ..
06/24 ASTELLAS UK : Suspension from Membership of the ABPI to be Extended for 12 Month..
06/23 ASTELLAS PHARMA : president wants people to focus on lives saved by pharmaceutic..
06/22 ASTELLAS PHARMA : Drug company president wants people to focus on lives saved by..
More news
News from SeekingAlpha
07/07 Big Cap Biopharma Ends The Half Year On A High Note
07/06 Applying 'Base And Swing' To Cytokinetics
06/30 Astellas submits sNDA for mirabegron in combination with solifenacin succinat..
06/29 Cytokinetics begins Phase 1b clinical trial of CK-2127107 in elderly subjects..
06/16 New Dogs For Old Tricks
Financials ( JPY)
Sales 2018 1 286 011 M
EBIT 2018 260 000 M
Net income 2018 198 617 M
Finance 2018 427 314 M
Yield 2018 2,62%
P/E ratio 2018 14,10
P/E ratio 2019 14,34
EV / Sales 2018 1,86x
EV / Sales 2019 1,79x
Capitalization 2 813 600 M
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 513  JPY
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-16.36%25 306
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303